Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors

Journal Article · Fri Dec 01 04:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.07.1373· OSTI ID:20850279

Suzuki, Minoru ^[1]; Sakurai, Yoshinori ^[2]; Nagata, Kenji ^[1]; Kinashi, Yuko ^[1]; Masunaga, Shinichiro ^[1]; Ono, Koji ^[1]; Maruhashi, Akira ^[2]; Kato, Ituro ^[3]; Fuwa, Nobukazu ^[4]; Hiratsuka, Junichi ^[5]; Imahori, Yoshio ^[6]

---

1. Particle Oncology Research Center, Research Reactor Institute, Kyoto University, Osaka (Japan)
2. Division of Medical Physics, Department of Radiation Life Science, Research Reactor Institute, Kyoto University, Osaka (Japan)
3. Department of Oral and Maxillofacial Surgery II, Osaka University Graduate School of Dentistry, Osaka (Japan)
4. Department of Radiation Oncology, Aichi Cancer Center, Aichi (Japan)
5. Department of Radiation Oncology, Kawasaki Medical School, Okayama (Japan)
6. Cancer Intelligence Care Systems, Inc., Tokyo (Japan)

Purpose: To analyze the dose-volume histogram (DVH) of head-and-neck tumors treated with boron neutron capture therapy (BNCT) and to determine the advantage of the intra-arterial (IA) route over the intravenous (IV) route as a drug delivery system for BNCT. Methods and Materials: Fifteen BNCTs for 12 patients with recurrent head-and-neck tumors were included in the present study. Eight irradiations were done after IV administration of boronophenylalanine and seven after IA administration. The maximal, mean, and minimal doses given to the gross tumor volume were assessed using a BNCT planning system. Results: The results are reported as median values with the interquartile range. In the IA group, the maximal, mean, and minimal dose given to the gross tumor volume was 68.7 Gy-Eq (range, 38.8-79.9), 45.0 Gy-Eq (range, 25.1-51.0), and 13.8 Gy-Eq (range, 4.8-25.3), respectively. In the IV group, the maximal, mean, and minimal dose given to the gross tumor volume was 24.2 Gy-Eq (range, 21.5-29.9), 16.4 Gy-Eq (range, 14.5-20.2), and 7.8 Gy-Eq (range, 6.8-9.5), respectively. Within 1-3 months after BNCT, the responses were assessed. Of the 6 patients in the IV group, 2 had a partial response, 3 no change, and 1 had progressive disease. Of 4 patients in the IA group, 1 achieved a complete response and 3 a partial response. Conclusion: Intra-arterial administration of boronophenylalanine is a promising drug delivery system for head-and-neck BNCT.

• OSTI ID: 20850279
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 66; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BORON
BORON COMPOUNDS
DRUGS
HEAD
NECK
NEOPLASMS
NEUTRON CAPTURE THERAPY
PATIENTS
PLANNING
RADIATION DOSES